HIV infection is the strongest risk factor for a person to develop tuberculosis (TB), and TB is responsible for over a quarter of all AIDS-related deaths worldwide. Treatment of latent TB infection with a drug called isoniazid is an inexpensive, effective prevention method used in the United States, Europe and elsewhere since the 1960s. Unfortunately, less than 0.1 percent of people with HIV who are eligible for isoniazid preventive treatment (IPT) are receiving treatment.

This e-learning course, awarded the Global Giveback Award in 2012, invites learners to navigate a series of scenarios in which they are given an abbreviated medical background and a list of current symptoms of an adult or child living with HIV. Course participants then determine whether to offer IPT, and if so, what the appropriate duration of treatment should be for each patient, in accordance with World Health Organization guidelines. Depending on the learner's pace and previous knowledge, the course requires 30 to 45 minutes to complete.

Isoniazid Preventive Therapy (IPT) for the Prevention of Tuberculosis in People Living with HIV